SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending with significant community buzz around its upward price movement and potential decoupling from major cryptocurrencies, fueled by discussions of a short squeeze. While some anticipate further gains and institutional adoption, including growing interest from firms like Goldman Sachs, others foresee a retracement, all within the broader context of impending regulatory clarity.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing heavy buying pressure and a rumored short squeeze, fueled by community discussion about a potential "COEP merger," though many investors debate if this rally is sustainable or a pump and dump.

WorldFinancial

Congressional scrutiny over a $500 million foreign investment and potential conflicts of interest is driving conversation around WorldFinancial (WLFI), with the community intensely debating its low token float, upcoming app/RWA launch, and bank charter application as potential catalysts for significant gains or confirmation of "scam" allegations.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the recent launch of its EVM-compatible JasmyChain mainnet, powered by JASMY as a gas token for AI and Web3 use cases, ignites both optimism for long-term utility and skepticism over its immediate price performance. The community is fiercely debating whether this fundamental development, alongside institutional recognition, signifies a genuine long-term build or another instance of a 'pump and dump' in a volatile crypto market.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as its recently FDA-approved drug, Yartemlea, has begun commercial sales as the first and only treatment for severe TA-TMA, driving community anticipation of significant revenue growth and potential acquisition interest from partners like Novo Nordisk. However, market conversations reflect frustration over artificial price suppression, linked to options dynamics and skepticism about initial market penetration, despite strong underlying fundamentals.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending following the clarified transition of its core developers to a new startup focused on scaling the protocol, which assuages prior concerns of abandonment and builds on the recent positive conclusion of the SEC's investigation. This development has ignited community discussions about Zcash's potential for wider adoption and its role in the evolving privacy coin landscape.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is generating significant buzz due to its highly volatile price action, with the community sharply divided between those who believe a 'meme coin season' is underway and are targeting massive gains, and those who are actively shorting it, while a distinct 'three frog' narrative also fuels conversation.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending as a major sovereign wealth fund's significant investment counters recent short-seller allegations, fueling community discussion around its strategic acquisitions to become a full-stack quantum leader. This development, coupled with high short interest, is generating buzz about a potential squeeze amidst broader government focus on advancing quantum computing.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as its critical oracle infrastructure and Cross-Chain Interoperability Protocol (CCIP) gain significant traction, with major institutions like Robinhood and Coinbase integrating its services for real-world asset tokenization and cross-chain transfers. Despite volatile price action, the community and large investors are actively accumulating, anticipating its solidified role as a backbone for future finance amid ongoing regulatory developments like the Clarity Act.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending due to widespread community discussion surrounding its pivotal role in SWIFT's digital asset interoperability pilots, positioning the Ethereum Layer-2 as a significant contender in institutional finance and sparking debate against rival crypto assets. While the project's strong fundamentals and deflationary tokenomics are fueling optimism, ongoing conversations also highlight concerns about token unlocks and market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 437,896 shares, an...

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of...

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 194,336 shares, a...

Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% - Here's Why

Repare Therapeutics (NASDAQ:RPTX) Shares Up 0.4% - Still a Buy...

Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw some unusual options trading on Wednesday. Stock investors bought 3,187 call options on the company. This represents an increase of 407...

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.read more...

<ul class="summary-bullets"><li>The deal includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.</li><li>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta.</li><li>The treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.</li></ul>Repare Therapeutics Inc. (RPTX) shares soared more than 21% in Wednesday’s pre-market trade after the company announced a deal with Gilead Sciences Inc. (GILD) for its investigational cancer treatment.Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million. This includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RPTX">Repare Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing.<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences shares</a> were up around 1% in Wednesday’s pre-market trade. Retail sentiment around the company trended in the ‘neutral’ territory.<h2 class="st-heading-2">More About Repare’s Cancer Treatment</h2>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta. This is associated with BRCA mutations and other genomic alterations.A BRCA mutation is a harmful change in the BRCA1 or the BRCA2 genes that increases the risk for several cancers, including breast, ovarian, prostate, pancreatic, and others. This mutation is inherited and has no symptoms.Repare’s treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.<h2 class="st-heading-2">Boosting Repare’s Cash Balance</h2>Repare stated that the Gilead deal has increased its cash balance, and it is the third portfolio deal entered into by the company this year.Following this deal, Repare estimates that its shareholders will receive $2.2 per share in the pending transaction with XenoTherapeutics Inc. Last month, XenoTherapeutics entered into a definitive agreement to acquire all the issued and outstanding common shares of Repare.Under the deal’s terms, Repare’s shareholders were expected to receive approximately $1.82 in cash per share, along with one non-transferable contingent value right (CVR) per common share. This CVR entitles holders to receive certain future cash payments over 10 years.<a href="https://stocktwits.com/symbol/RPTX">RPTX stock</a> is up 61% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> is up 34%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-stock-market-open-on-christmas-eve/cLesMeFREv2">Is The Stock Market Open Today? Here Are NYSE, Nasdaq Trading Hours On Christmas Eve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Equity

Repare Therapeutics Announces Acquisition of Pol ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to...

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE...

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Repare Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

RPTX
Repare Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RPTX News

RPTXRepare Therapeutics Inc